Regeneron Pharmaceuticals, Inc.
About Regeneron
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for treating various diseases worldwide.
The company's product portfolio includes:
-
EYLEA injection: Treats wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy and macular edema following retinal vein occlusion.
-
Dupixent injection: Used for atopic dermatitis and asthma in adults and children.
-
Libtayo injection: Treats metastatic or locally advanced cutaneous squamous cell carcinoma.
-
Praluent injection: Targets heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults.
-
REGEN-COV: A treatment for COVID-19.
-
Kevzara solution: For treating rheumatoid arthritis in adults.
-
Inmazeb injection: Treats infections caused by Zaire ebolavirus.
-
ARCALYST injection: For cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome.
-
ZALTRAP injection: For intravenous infusion to treat metastatic colorectal cancer.
The company is also developing product candidates for treating eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; as well as cancer, pain, and hematologic conditions.
Regeneron has collaboration and license agreements with several notable companies, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Roche Pharmaceuticals and Kiniksa Pharmaceuticals. It also collaborates with the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Biomedical Advanced Research Development Authority and AstraZeneca PLC.
Founded in 1988, Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, New York.
Regeneron's Business Strategy
Regeneron operates with a science-driven innovation strategy anchored by its proprietary VelociSuite technology platforms, which enable rapid antibody development and validation. The company maintains an integrated model controlling research, development, and manufacturing to accelerate the translation of scientific discoveries into commercial therapies.
Revenue generation comes primarily…
Available on Finplify
Free account required
Our Take on Regeneron
Pros:
✅ Innovation-Led Biotech: Regeneron has built a reputation for scientific excellence, particularly in monoclonal antibodies and genetics-driven drug discovery. Its proprietary VelociSuite® technologies allow for rapid development and high productivity in biologics R&D.
✅ Blockbuster Portfolio with Multiple Growth Drivers: The company’s portfolio includes major…
Available on Finplify
Free account required
Company Details
Key Metrics
Fundamental Analysis
Proprietary 5-category scoring system
Score Fingerprint
Section Scores
Full Breakdown & Peer Ranking
See the detailed score for every metric and how this stock ranks against its sector peers
Unlock the full research on Regeneron
Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.
300+ Curated Stocks
A hand-picked universe of world-class businesses across every major market and sector.
AI Analyst Briefings
Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.
Proprietary Fundamentals
Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.